 "Best of BS Opinion: Covaxin gets a booster, pandemic risk in IPOs, and more")
After a long delay, the World Health Organization has approved the Indian-manufactured vaccine Covaxin for emergency use. Scaling this hurdle – finally -- raises key questions about the next steps in the Covid-19 vaccination programme. The top edit outlines the key issues here.
In other views:
The prime minister’s Panchamrita pledge at Glasgow burnishes India’s climate credentials, but a perilous future awaits the world. Shyam Saran discusses what’s at stake. Read it here
The second edit explains how the renaming of Facebook will help the social media giant in multiple ways. Read it here
Covid-19 is a standard fixture in all IPO prospectuses hitting the market. Who will be the first to say the pandemic is a thing of the past, asks Nivedita Mookerji. Read it here
QUOTE OF THE DAY‘They didn’t show up… It is a gigantic issue and they just walked away’US President Joe Biden on Xi Jinping’s absence at COP26
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%